EGFR and cancer: We chose 100 nM (15 μg/ml) dose of cetuximab for additional studies because this is a receptor saturating concentration optimal to inhibit growth of EGFR-dependent cancer cells in culture [22] and achieved at steady-state in the plasma of patients receiving cetuximab [23].